SF3B4 Rabbit anti-Human, Mouse, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA528441
PA5-28441 targets SF3B4 in IF and WB applications and shows reactivity with Human and mouse samples. The PA5-28441 immunogen is synthetic peptide corresponding to a region within amino acids 1 and 44 of Human SF3B4. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial. For short-term storage (1-2 weeks), product can be stored at 4°C. For long-term storage, aliquot and store product at -20° C or below, avioiding multiple freeze-thaw cycles.This gene encodes one of four subunits of the splicing factor 3B. The protein encoded by this gene cross-links to a region in the pre-mRNA immediately upstream of the branchpoint sequence in pre-mRNA in the prespliceosomal complex A. It also may be involved in the assembly of the B, C and E spliceosomal complexes. In addition to RNA-binding activity, this protein interacts directly and highly specifically with subunit 2 of the splicing factor 3B. This protein contains two N-terminal RNA-recognition motifs (RRMs), consistent with the observation that it binds directly to pre-mRNA.
|Synthetic peptide corresponding to a region within amino acids 1 and 44 of Human SF3B4|
|Antigen affinity chromatography|
|Immunocytochemistry, Immunofluorescence, Western Blot|
|0.1M tris glycine with 10% glycerol and 0.01% thimerosal; pH 7|
|Hsh49, SAP49, SF3b49, SAP 49, SF3b50, pre-mRNA splicing factor SF3b 49 kDa subunit, pre-mRNA-splicing factor SF3b 49 kDa subunit, spliceosomal protein, spliceosome-associated protein (U2 snRNP), spliceosome-associated protein 49, splicing factor 3B subunit 4|
|Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok